Seismic Therapeutic Selected for BioSpace’s NextGen Class of 2023

Cambridge, Mass., January 4, 2023 – Seismic Therapeutic, Inc., a biotechnology company advancing machine learning for immunology drug development, announced today it has been selected for BioSpace’s NextGen “Class of 2023” featuring the 25 most promising new life sciences companies in North America that launched between September 2021 and September 2022 with a Series A funding.

“At a time when there is so much exciting scientific innovation in the biopharma industry, we are honored to be recognized as one of the most promising New Life Science Companies on the BioSpace NextGen Class of 2023 List,” said Jo Viney, PhD, CEO of Seismic Therapeutic. As we start the new year, I and our growing, dedicated team of Seismonauts are energized to continue to rapidly advance our pipeline of innovative immunology therapies derived from our IMPACT platform.”

BioSpace has been recognizing the most exciting startups in biotech and pharma for the past nine years in its NextGen list. Organizations across all therapeutic areas are considered, and 25 companies were selected this year. BioSpace’s editorial team analyzed multiple components as determining factors: finance, collaborations, pipeline, growth potential and innovation.

The complete NextGen “Class of 2023” list can be viewed on BioSpace.

About BioSpace

BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. Learn more and subscribe at

About Seismic Therapeutic
Seismic Therapeutic is a biotechnology company integrating machine learning across the entire biologics discovery process to accelerate immunology drug development. Using its IMPACT™ platform, the company is addressing the central challenges of biologics discovery and development by fully integrating machine learning with the key elements of biologics drug discovery – structural biology, protein engineering and translational immunology – to create optimized therapies on an accelerated path to patients. Seismic Therapeutic has an emerging pipeline of novel biologics to treat adaptive immune system dysregulation to treat autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit

Media Contact
Kathryn Morris, The Yates Network


This links to an external website.